SCNI vs PLUR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SCNI Captures Institutional Edge (2โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI) driven by superior Growth & Margin, Momentum & Technical while PLUR counters with relative strength in Valuation. Fundamentally, SCNI trades at N/M Forward P/E with -276.1% operating margin (+572.5% YoY revenue) versus PLUR at 3.6x Forward P/E and -2454.5% operating margin (-15.8% YoY). In options structure, SCNI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PLUR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SCNI | PLUR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.1M | $15.1M | Larger Scale | PLUR |
| Trailing P/E Ratio Valuation | 0.1x | 3.6x | Lower Multiple | SCNI |
| Forward P/E Ratio Valuation | N/M | 3.6x | Lower Multiple | PLUR |
| Revenue Growth (YoY) Growth | +572.5% | -15.8% | Higher Growth | SCNI |
| Operating Margin (TTM) Profitability | -276.1% | -2454.5% | Higher Margin | SCNI |
| Net Profit Margin Profitability | -80.1% | 0.0% | Higher Margin | PLUR |
| Return on Equity (ROE) Capital Efficiency | -26.1% | -1022.0% | Higher ROE | SCNI |
| 52-Week Range Position Momentum | 5% ($0โ$4) | 2% ($1โ$5) | Stronger Trend | SCNI |
| Beta / 30D Volatility Risk Regime | 3.85ฮฒ ยท 82% Vol | 0.80ฮฒ ยท 102% Vol | Lower Realized Risk | SCNI |
| Unified Institutional Score Composite Signal | 47.3 / 100 (HOLD) | 28.8 / 100 (SELL) | Higher Composite | SCNI |